Gerald S. Asin, M.D.
Cognitive Clinical Trials Research
8901 E. Pima Center Parkway, Suite 115
Scottsdale, AZ 85258

CONTACT INFORMATION:

Site Selection and Information:
Bobbie Theodore, Alliance Director
Tel. (916) 939-6696
Fax (208) 575-3169
Email: clinicaltrials@alliancesites.com

AFFILIATIONS:

Stonecreek Medical Associates
10565 N. Tatum Blvd., Suite B-116
Paradise Valley, AZ 85253

EDUCATION:

1983 – 1987 Doctor of Medicine
University of Oklahoma College of Medicine, Oklahoma City, OK

1979 – 1983 Bachelor of Science, Classics
Northwestern University, Evanston, IL

INTERNSHIP AND RESIDENCY:

1987- 90 Internship and Residency, Internal Med
Medical College of Wisconsin, Milwaukee, WI

CERTIFICATION AND LICENSURE:

2017 Elected to Fellowship, American College of Physicians
1990 Board Certified American College of Physicians, Recertified 2000, 2010
1990 Board of Medical Examiners of the State of Arizona, Certificate number (20348)

PROFESSIONAL EXPERIENCE:

Principal Investigator, Sub-Investigator, 2019 – Present
Cognitive Clinical Trials Research, Paradise Valley, AZ

Owner/Physician Internal Med, 2002 – Present
Stonecreek Medical Associates, Paradise Valley, AZ

PROFESSIONAL EXPERIENCE (*continued*):

Sub-Investigator/Internist, 2016 – Present
Noesis Pharma, LLC, Phoenix, AZ

Principal/Sub-Investigator, 2007 – 2014
Clinical Research Advantage, Phoenix, AZ

Principal/Sub-Investigator, 2007 – 2015
Radiant Research, Phoenix, AZ

Practicing Physician, Internal Med, 1995 – 2002
Scottsdale Healthcare Family Care, Phoenix, AZ

Practicing Physician, Internal Med, 1992 – 1995
Arizona Physicians Center, Phoenix, AZ

Practicing Physician, Internal Med, 1990 – 1992
Locum Tenens Physician, Salt Lake City, UT

INVESTIGATOR EXPERIENCE:

Asthma • Depression • Diabetes • Fibromyalgia • Hyperlipidemia • Hypertension
Opioid Induced Bowel Dysfunction • Osteoarthritis • Vaccine

ADDITIONAL INVESTIGATOR EXPERIENCE:

Hypercholesterolemia, • Obesity • Dyslipidemia

INVESTIGATOR EXPERIENCE:

Asthma

A Randomized, Double Blind, Double Dummy, Placebo-Controlled, Parallel-Group, Multicenter, Dose Ranging Study to Evaluate the Efficacy and Safety of XXX Inhalation Powder Once Daily and XXX Inhalation Powder 500mcg Twice Daily Compared with Placebo for 8 weeks in Adolescent and Adult Subjects with Persistent Asthma Symptomatic on Moderate Dose ICS therapy

A Randomized, Double Blind, Double Dummy, Placebo-Controlled, Parallel-Group, Multicenter, Dose Ranging Study to Evaluate the Efficacy and Safety of XXX Inhalation Powder Once Daily and XXX Inhalation Powder 250rncg Twice Dally compared with Placebo for 8 Weeks in Adolescent and Adult Subject with Persistent Asthma Symptomatic on Low Dose ICS therapy

INVESTIGATOR EXPERIENCE (*continued*):

A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, Multicenter, Dose Ranging Study to Evaluate the Efficacy and Safety of XXX Inhalation Powder Once Daily and XXX Inhalation Powder 100mcg Twice Daily compared with Placebo for 8 Weeks in Adolescent and Adult Subject with Persistent Asthma Symptomatic on Non-Steroidal, Asthma Therapy

Depression

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Relapse-Prevention Study with XXX-XXX in patients with Major Depressive Disorder

Diabetes

Natural History Study of the Development of Type 1 Diabetes Phase II: Baseline Risk Assessment for Type 1 Diabetes

A Phase IIIb, Double-Blind, Randomized Study to Determine the Efficacy and Safety of XXX and Metformin Fixed -Dose Combination Therapy Compared to XXX and to Metformin Monotherapy in the Treatment of Subjects with Type 2 Diabetes

Fibromyalgia

A Randomized, Double-Blind, Placebo and Active Controlled Study of XXX-XXX in Subjects with Pain Associated with Fibromyalgia

An Open-Label Extension of XXX-XXX for 52 Week in Pain Associated with Fibromyalgia Effect of XXX 30/150 mg Once Daily versus Placebo in Adolescents with Juvenile Primary Fibromyalgia Syndrome

Hyperlipidemia

A Multi-Center, Randomized, Double-Blind, Parallel Group, 12 Week Study to Evaluate the Efficacy and Safety of XXX vs Atorvastatin in Patients with Mixed Hyperlipidemia

Hypertension

A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of XXX When Co-Administered with XXX in Subjects with Essential Hypertension

A Randomized, Double-Blind, Parallel-Group Study Evaluating the Efficacy and Safety of Co-Administration of a Triple Combination Therapy of XXX and Hydrochlorothiazide in Subjects with Hypertension

INVESTIGATOR EXPERIENCE (*continued*):

Osteoarthritis

A Phase III, Flexible-Dose Titration Followed by A Randomized Double-Blind Study of Controlled-Release XXX-XXX Compared to Placebo in Patients with Osteoarthritis Pain

Other Indications

A Multicenter, Open-Labeled Study of the Long-Term Safety and Efficacy of XXX in Patients with Opioid Induced Bowel Dysfunction

A Phase III, Open-Label, Single-Arm Trial Evaluating the Safety, Tolerability and Reactogenicity of XXX Pneumococcal Conjugate Vaccine in Ambulatory Elderly Adults aged 70 years and Older Who Received 1 Dose of XXX Pneumococcal Polysaccharide Vaccine at Least 5 Years Before Study Enrollment